Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) was the target of a significant increase in short interest in the month of December. As of December 30th, there was short interest totalling 1,180,000 shares, an increase of 12.4% from the December 15th total of 1,050,000 shares. Approximately 7.0% of the company's shares are sold short. Based on an average daily volume of 86,700 shares, the short-interest ratio is currently 13.6 days.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH lowered their price target on Aadi Bioscience to $47.00 in a research report on Tuesday, November 15th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AADI. RA Capital Management L.P. raised its stake in Aadi Bioscience by 54.1% during the third quarter. RA Capital Management L.P. now owns 590,218 shares of the company's stock valued at $8,340,000 after buying an additional 207,190 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Aadi Bioscience by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 567,129 shares of the company's stock valued at $8,014,000 after buying an additional 25,085 shares in the last quarter. State Street Corp raised its stake in Aadi Bioscience by 72.0% during the first quarter. State Street Corp now owns 535,578 shares of the company's stock valued at $9,089,000 after buying an additional 224,178 shares in the last quarter. Ikarian Capital LLC raised its stake in Aadi Bioscience by 97.9% during the second quarter. Ikarian Capital LLC now owns 412,343 shares of the company's stock valued at $1,274,000 after buying an additional 203,975 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Aadi Bioscience by 1.6% during the third quarter. Price T Rowe Associates Inc. MD now owns 251,279 shares of the company's stock valued at $3,552,000 after buying an additional 4,041 shares in the last quarter. Institutional investors and hedge funds own 67.09% of the company's stock.

Aadi Bioscience Trading Up 1.8 %

Aadi Bioscience (NASDAQ:AADI – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. The company had revenue of $4.25 million for the quarter, compared to analysts' expectations of $3.60 million. Aadi Bioscience had a negative return on equity of 44.28% and a negative net margin of 569.57%. Equities analysts forecast that Aadi Bioscience will post -2.86 EPS for the current fiscal year.

Aadi Bioscience Company Profile

(Get Rating)

Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Further Reading

• Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.